单细胞技术揭示的非小细胞肺癌免疫生物学：对接受免疫疗法治疗的患者生物标志物发展的启示。
Immune biology of NSCLC revealed by single-cell technologies: implications for the development of biomarkers in patients treated with immunotherapy.
发表日期：2023 Jan
作者：
J Wlosik, S Fattori, P Rochigneux, A Goncalves, D Olive, A S Chretien
来源：
Seminars in Immunopathology
摘要：
非小细胞肺癌的一线免疫治疗大大改善了患者的生存率。在启动免疫检查点抑制剂之前，需要进行PD-L1检测。然而，该生物标志物无法准确预测患者的反应。另一方面，免疫治疗会让患者暴露于免疫相关毒性，其机制仍不清楚。因此，需要开发临床批准的预测生物标志物，以更好地选择从免疫检查点抑制剂中受益最大的患者，并改善风险管理。单细胞技术为肿瘤及其微环境提供了前所未有的洞察力，导致发现与免疫检查点抑制剂反应或毒性有关的免疫细胞。在本综述中，我们将强调单细胞方法的潜力，以识别改善非小细胞肺癌患者护理的候选生物标志物。©2022年，作者。
First-line immunotherapy in non-small-cell lung cancer largely improved patients' survival. PD-L1 testing is required before immune checkpoint inhibitor initiation. However, this biomarker fails to accurately predict patients' response. On the other hand, immunotherapy exposes patients to immune-related toxicity, the mechanisms of which are still unclear. Hence, there is an unmet need to develop clinically approved predictive biomarkers to better select patients who will benefit the most from immune checkpoint inhibitors and improve risk management. Single-cell technologies provide unprecedented insight into the tumor and its microenvironment, leading to the discovery of immune cells involved in immune checkpoint inhibitor response or toxicity. In this review, we will underscore the potential of the single-cell approach to identify candidate biomarkers improving non-small-cell lung cancer patients' care.© 2022. The Author(s).